Press Release

     View printer-friendly version
    << Back
    Blueprint Medicines to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, March 9, 2017

    CAMBRIDGE, Mass., March 2, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 9, 2017 to report its fourth quarter and full year 2016 financial results and provide a corporate update.

    Blueprint Medicines

    To access the live conference call, please dial 1-855-728-4793 (domestic) or 1-503-343-6666 (international), and refer to conference ID 66277428. A webcast of the call will also be available on the Investors section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

    About Blueprint Medicines

    Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing four clinical trials for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer and medullary thyroid cancer, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.

    To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-report-fourth-quarter-and-full-year-2016-financial-results-on-thursday-march-9-2017-300416666.html

    SOURCE Blueprint Medicines Corporation

    Investor Relations: Kristin Williams, Blueprint Medicines Corporation, 617-714-6674, kwilliams@blueprintmedicines.com; Media Relations: Rachel Hutman, W20 Group, 301-801-5540, rhutman@wcgworld.com



    Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | Financial Tear Sheet